MyMedR

Displaying publications 21 - 23 of 23 in total

Abstract:

Sort:

Lactobacillus probiotics restore vaginal and gut microbiota of pregnant women with vaginal candidiasis

Ang XY, Roslan NS, Ahmad N, Yusof SM, Abdullah N, Nik Ab Rahman NN, et al.

Benef Microbes, 2023 Nov 23;14(5):421-431.
PMID: 38350486 DOI: 10.1163/18762891-20220103

The development of probiotics has now included the areas along the gut-vaginal axis. We thus aimed to investigate the effects of lactobacilli probiotic to modulate and restore vaginal and gut microbiota of pregnant women with vaginal candidiasis (VC). A randomised, double-blind and placebo-controlled study was performed in 78 pregnant women with VC. Patients were randomised to either the probiotic (SynForU-HerCare) or placebo which were administered at baseline and continued for 8-weeks (two capsules/day of 9.5 log cfu/capsule). Microbiota profiles were assessed at time points of weeks-0, 4 and 8 for high vaginal swab and faecal samples. Shannon diversity index showed that after 8-weeks amid VC, a shift in microbial community compositional changes occurred in the high vaginal region at both genus (P=0.025) and species (P=0.044) levels, where the administration of probiotic prevented such a shift. These changes were mainly attributed to a decreased in abundance of Lactobacillus (P=0.042) accompanied by increased abundance of Prevotella (P=0.002) and Atopobium (P=0.002) in the placebo group while the probiotic group remained unchanged over time. The administration of probiotics also prevented a reduced abundance of faecal phylum Firmicutes after 8-weeks as seen in the placebo group (P<0.0001), which also showed reduction at subsequent taxonomic levels of class, family, genera and species. VC has not only altered the microbiota of vagina regions but also gut microbiota profiles, causing lessening of gut microbiota that are crucial for gut nutrient availability, protection and immunity. The administration of lactobacilli probiotics has prevented such a shift, leading to better modulated gut and vaginal microenvironment amid VC. The study was registered at ClinicalTrials.gov: identifier number NCT03940612.
Probiotic enhanced immunity and mental wellbeing of generally healthy women: a randomised, placebo-controlled and double-blind study

Nisaa AA, Mageswary U, Pei X, Kadir MN, Oon CE, Rajendran D, et al.

Benef Microbes, 2025 Feb 24.
PMID: 40008414 DOI: 10.1163/18762891-bja00061

The elucidation of the gut-brain axis underscores the critical role of probiotics in enhancing mental wellbeing through immunomodulatory mechanisms. We thus aimed to investigate the effects of a probiotic Lactiplantibacillus plantarum Probio87 (orally administered one sachet/day; 9 log cfu/sachet) or placebo for 12-weeks, on immunity and brain health, via possible mechanisms of inflammation and neurotransmitter functions in a generally healthy women population. A parallel, randomised, double-blind and placebo-controlled study was performed in generally healthy women (n = 112). Women were randomised to either the probiotic (n = 58, mean age 38.38 ± 0.85 years) or placebo (n = 54, mean age 38.91 ± 0.98 years) for 12-weeks. Immunity and mental wellbeing profiles were evaluated via questionnaires and blood gene expression profiles. Over the study period, the Probio87 group demonstrated a better impact on general women's health as compared to the control group, as measured by the Women's Health Questionnaire (WHQ), particularly in domains related to depressed mood, somatic symptoms, anxiety, sexual health, sleep, and menstrual health. The probiotic effects were exhibited later, typically after 6-weeks of intervention, taking over placebo effects that primarily faded off during early stages of the intervention. Regarding immunity, women in the Probio87 group exhibited upregulation of more immunity-related genes than those in the placebo group, primarily associated with NK cells and anti-inflammatory effects via IL-10. Additionally, Probio87 provided gut-brain axis benefits by enhancing the actions of neurotransmitters serotonin and GABA, while also balancing hunger and satiety. The probiotic Lactiplantibacillus plantarum Probio87 significantly improved general health, mood, anxiety, and sleep in a generally healthy women population over 12 weeks. It enhanced immune function through increased expression of immunity-related genes and positively modulated neurotransmitters involved in brain health. All these findings supported from our WHQ data, where the administration of probiotic improved domains related to depressed mood, anxiety, sexual behaviour and sleep problems. The study is registered at ClinicalTrials.gov under identifier number: NCT05302687.
Lactobacilli reduce recurrences of vaginal candidiasis in pregnant women: a randomized, double-blind, placebo-controlled study

Ang XY, Chung FY, Lee BK, Azhar SNA, Sany S, Roslan NS, et al.

J Appl Microbiol, 2021 May 22.
PMID: 34022103 DOI: 10.1111/jam.15158

AIMS: The aim of this study was to investigate the effects of lactobacilli strains in preventing the recurrences of vaginal candidiasis (VC) in 78 pregnant women with VC (lactobacilli, n = 39; placebo, n = 39) and the potential benefits on quality of life.
METHODS AND RESULTS: The lactobacilli putative probiotic (SynForU-HerCare; two capsules/day of 9·5 log CFU per capsule) or placebo was administered for 8-weeks in a randomized, double-blind, placebo-controlled study. Subjects were assessed for vaginal and gut health conditions at baseline, week-4 and week-8 via questionnaires. The vulvovaginal symptom questionnaire not only covered aspects pertaining to vulvovaginal symptoms but also the quality of life impacts such as emotional, social and sexual. The administration of lactobacilli reduced symptoms of irritation (P = 0·023) and discharge (P = 0·011) starting week-4 and continued after week-8 (P

Filters

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links